$ News

Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Avidity Biosciences Final Results From Phase 1/2 MARINA Trials Will Be Published In The New England Journal Of Medicine February 19th

Reported Earlier, Avidity Biosciences Sets Record Date of February 12, 2026 For Spin-Off Of Atrium Therapeutics Shares To Stockholders

Immunocore (IMCR) Soars 5.9%: Is Further Upside Left in the Stock?

JPM26: Novartis strengthens neuroscience portfolio with bolt-on deals

Top 2 Health Care Stocks That May Keep You Up At Night In December

Assessing Avidity Biosciences (RNA) Valuation After a 130% Year-to-Date Share Price Surge

Here's How Much $100 Invested In Avidity Biosciences 5 Years Ago Would Be Worth Today

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

Looking Into Avidity Biosciences Inc's Recent Short Interest

Avidity Biosciences Announces MAP For Investigational Therapy Delpacibart Zotadirsen For Eligible People With Duchenne Muscular Dystrophy Mutations Amenable To Exon 44 Skipping In US

Should You Rethink Avidity Biosciences After 127% Rally on Trial Breakthroughs?

Chardan Capital Maintains Neutral on Avidity Biosciences, Maintains $72 Price Target

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates

Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

Avidity Biosciences Q3 EPS $(1.27) Misses $(1.11) Estimate, Sales $12.475M Beat $1.932M Estimate

Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger

Exploring Avidity Biosciences (RNA) Valuation Following Recent Share Price Surge

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)

Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for